Accession Number : ADA441351


Title :   Real-Time Dosimetry and Optimization of Prostate Photodynamic Therapy


Descriptive Note : Annual rept. 1 May 2004-30 Apr 2005


Corporate Author : PENNSYLVANIA UNIV PHILADELPHIA


Personal Author(s) : Zhu, Timothy C


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/a441351.pdf


Report Date : May 2005


Pagination or Media Count : 81


Abstract : For the second year of this 3-year grant. We have completed specific aim 2 of the project, i.e., light dose calculation and optimization, and characterization of photosensitizer drug concentration. We have improved the motorized probe and associate software to measure the distribution of optical properties, drug concentration, and StO2 interstitially. We have developed a fluorescence technique to measure in-vivo phototosensitizer distribution interstitially in 5 patients and have verified its accuracy using the absorption spectra. We have also developed software to automatically optimize the light source weights, lengths, strengths in near real-time to improve the light fluence rate distribution in prostate and spare dose to critical structures. We have compared the measurement and calculation of in-vivo light fluence rate in 14 patients assuming homogeneous optical properties in prostate. Our measurements demonstrate heterogeneity in both the optical properties and the photosensitizer distribution. Thus, we concluded that it is necessary to determine the 3D distribution of optical properties and drug concentration in order to optimize the PDT dose distribution for each individual patient.


Descriptors :   *PROSTATE CANCER , COMPUTER PROGRAMS , MEASUREMENT , OPTICAL PROPERTIES , FLUORESCENCE , REAL TIME , DISTRIBUTION , STRUCTURES , RATES , ACCURACY , LIGHT SOURCES , WEIGHT , DOSAGE , ABSORPTION SPECTRA , DRUGS , IN VIVO ANALYSIS , CONCENTRATION(CHEMISTRY) , SPARE PARTS , HOMOGENEITY , PROSTATE GLAND , PHOTOSENSITIVITY , DOSIMETRY , RADIOTHERAPY


Subject Categories : Anatomy and Physiology
      Medicine and Medical Research


Distribution Statement : APPROVED FOR PUBLIC RELEASE